跳至主要内容
临床试验/CTRI/2025/03/083024
CTRI/2025/03/083024招募中不适用

UV-Femtosecond Laser Assisted Lenticule Extraction Astigmatism NomogramStudy in Subjects With Myopia

Alcon Laboratories Inc2 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2025年3月29日最近更新:

试验速览

阶段
不适用
状态
招募中
入组人数
80
试验地点
2
主要终点
1. Astigmatism subjective (manifest dry) manifest refraction at postoperative follow-up visits

研究概览

简要总结

The purpose of this study is to obtain additional safety and effectiveness data on the WaveLight® Ultraviolet Femtosecond Laser System (UV fs-Laser) lenticule extraction procedure to assess the accuracy and assist in developing of the astigmatism nomogram across a defined dioptric range.

The treatment range is -0.5 to -10.0 diopters (D) spherical component and -0.25 to -2.0 D cylinder component of the manifest refraction. Subjects will undergo lenticule extraction treatment in the study eye and, if needed, a suitable approved refractive therapy in the fellow eye. Subjects will be expected to attend at least 7 scheduled study visits: A screening visit, a surgery visit, and 5 post-operative visits (Day 1, Week 1, Month 1, Month 3, Month 6) for an individual total duration of participation of approximately 7 months.

__PRESENT

研究设计

研究类型
Interventional
分配方式
Not Applicable
盲法
Open Label

入排标准

年龄范围
18.00 Year(s) 至 99.00 Year(s)(—)
性别
All

入选标准

  • Myopia with sphere of -0.50 to -10.0 diopter and cylinder -0.25 to -2.0 diopter in study eye.
  • Stable refraction in the study eye.
  • Nondominant eye must qualify for treatment.
  • BCDVA better or Equal 0.14 logMAR in study and fellow eyes UCDVA Worse or equal 0.30 logMAR in study eye Presence of clear natural lens (non-cataractous eye) in study eye.
  • Minimum required endothelial cell density in study eye within defined age ranges.

排除标准

  • Study eye unable to focus for imaging and or treatment.
  • Acute or chronic disease or illness that would increase the operative risk or confound the outcomes of the study.
  • Current use of medications with known ocular side effects and photosensitivity.
  • Ocular conditions in the either eye that may affect subject safety or impact study outcomes.
  • Previous ocular surgery in the study eye that resulted in corneal distortions within the treatment zone.

结局指标

主要结局

1. Astigmatism subjective (manifest dry) manifest refraction at postoperative follow-up visits

时间窗: 1. Week 1, Month 1, Month 3, Month 06 | 2. Week 1, Month 1, Month 3, Month 06 | 3. From time of consent to study exit (cumulative to Month 6 postoperative)

[Time Frame: Week 1, Month 1, Month 3, Month 6]

时间窗: 1. Week 1, Month 1, Month 3, Month 06 | 2. Week 1, Month 1, Month 3, Month 06 | 3. From time of consent to study exit (cumulative to Month 6 postoperative)

2. Best Corrected Distance Visual Acuity (BCDVA) at postoperative follow-up visits

时间窗: 1. Week 1, Month 1, Month 3, Month 06 | 2. Week 1, Month 1, Month 3, Month 06 | 3. From time of consent to study exit (cumulative to Month 6 postoperative)

3. Ocular Serious Adverse Events

时间窗: 1. Week 1, Month 1, Month 3, Month 06 | 2. Week 1, Month 1, Month 3, Month 06 | 3. From time of consent to study exit (cumulative to Month 6 postoperative)

次要结局

  • 1. Spherical subjective (manifest dry) refraction at postoperative follow-up visits(2. Uncorrected Distance Visual Acuity at all postoperative follow-up visits)

研究者

申办方类型
Pharmaceutical industry-Global

研究点 (2)

Loading locations...

相似试验